AbbVie (ABBV) Long-Term Investments (2012 - 2026)

AbbVie has disclosed Long-Term Investments across 15 years of filings, most recently posting $268.0 million for Q1 2026.

• In Q1 2026, Long-Term Investments fell 6.62% year-over-year to $268.0 million; the TTM figure through Mar 2026 stood at $268.0 million (down 6.62% YoY), while the FY2025 annual figure was $268.0 million, down 3.94% from the prior year.
• Long-Term Investments held at $268.0 million in Q1 2026, from $268.0 million in the prior quarter.
• Over the last five years, Long-Term Investments for ABBV reached as high as $310.0 million in Q2 2025 and fell as low as $235.0 million in Q3 2022.
• The 5-year median for Long-Term Investments is $272.0 million (2024), against an average of $273.6 million.
• Annual changes were most pronounced in 2022 — Long-Term Investments retreated 14.75% — and 2023, when it grew 26.14%.
• A 5-year view of Long-Term Investments shows it stood at $241.0 million in 2022, then climbed by 26.14% to $304.0 million in 2023, then decreased by 8.22% to $279.0 million in 2024, then dropped by 3.94% to $268.0 million in 2025, then changed by 0.0% to $268.0 million in 2026.
• According to Business Quant data, Long-Term Investments over the past three periods registered $268.0 million, $268.0 million, and $291.0 million for Q1 2026, Q4 2025, and Q3 2025 respectively.